A Study of the Efficacy and Safety of Aricept in Patients With Severe Alzheimer's Disease Who Are Living in Skilled Nursing Homes

Pfizer

Status and phase: Completed; Phase 3

Conditions: Alzheimer Disease

Treatments: Drug: Placebo; Drug: Donepezil (Aricept)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00630851

A2501017

Details and patient eligibility

About

The purpose of the study is to evaluate the efficacy and safety of Aricept in nursing home patients with severe Alzheimer's disease.

Enrollment: 249 patients

Sex: All

Ages: 50+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Probable or possible Alzheimer's disease
• Living in skilled nursing home

Exclusion criteria

• Other types of dementia or psychiatric or neurologic disorders
• Musculoskeletal disease

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

249 participants in 2 patient groups, including a placebo group

1

Experimental group

Treatment:

Drug: Donepezil (Aricept)

2

Placebo Comparator group

Treatment:

Drug: Placebo